Trial · NCT04338321
Adverse events90
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 90
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Esketamine Nasal Spray + Oral Antidepressant (AD) | 63 | 334 | |
| other | Vertigo | Ear and labyrinth disorders | Quetiapine Extended Release (XR) + Oral AD | 3 | 336 | |
| other | Vision blurred | Eye disorders | Esketamine Nasal Spray + Oral Antidepressant (AD) | 21 | 334 | |
| other | Vision blurred | Eye disorders | Quetiapine Extended Release (XR) + Oral AD | 3 | 336 | |
| other | Dry mouth | Gastrointestinal disorders | Esketamine Nasal Spray + Oral Antidepressant (AD) | 3 | 334 | |
| other | Dry mouth | Gastrointestinal disorders | Quetiapine Extended Release (XR) + Oral AD | 22 | 336 | |
| other | Nausea | Gastrointestinal disorders | Esketamine Nasal Spray + Oral Antidepressant (AD) | 98 | 334 | |
| other | Nausea | Gastrointestinal disorders | Quetiapine Extended Release (XR) + Oral AD | 12 | 336 | |
| other | Vomiting | Gastrointestinal disorders | Esketamine Nasal Spray + Oral Antidepressant (AD) | 36 | 334 | |
| other | Vomiting | Gastrointestinal disorders | Quetiapine Extended Release (XR) + Oral AD | 5 | 336 | |
| other | Fatigue | General disorders | Esketamine Nasal Spray + Oral Antidepressant (AD) | 19 | 334 | |
| other | Fatigue | General disorders | Quetiapine Extended Release (XR) + Oral AD | 34 | 336 | |
| other | COVID-19 | Infections and infestations | Esketamine Nasal Spray + Oral Antidepressant (AD) | 24 | 334 | |
| other | COVID-19 | Infections and infestations | Quetiapine Extended Release (XR) + Oral AD | 29 | 336 | |
| other | Nasopharyngitis | Infections and infestations | Esketamine Nasal Spray + Oral Antidepressant (AD) | 21 | 334 | |
| other | Nasopharyngitis | Infections and infestations | Quetiapine Extended Release (XR) + Oral AD | 11 | 336 | |
| other | Blood pressure increased | Investigations | Esketamine Nasal Spray + Oral Antidepressant (AD) | 28 | 334 | |
| other | Blood pressure increased | Investigations | Quetiapine Extended Release (XR) + Oral AD | 4 | 336 | |
| other | Weight increased | Investigations | Esketamine Nasal Spray + Oral Antidepressant (AD) | 9 | 334 | |
| other | Weight increased | Investigations | Quetiapine Extended Release (XR) + Oral AD | 42 | 336 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04338321/events